BEL FUSE INC /NJ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BEL FUSE INC /NJ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $119.94M | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | $126.39M | Mar 9, 2018 |
| FY2017 | Jun 30, 2017 | $131.62M | Mar 9, 2018 |
| FY2017 | Mar 31, 2017 | $113.67M | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | $118.54M | Mar 9, 2018 |
| FY2017 | Sep 30, 2016 | $128.81M | Mar 9, 2018 |
| FY2017 | Jun 30, 2016 | $131.62M | Mar 9, 2018 |
| FY2017 | Mar 31, 2016 | $121.18M | Mar 9, 2018 |
| FY2016 | Dec 31, 2015 | $135.25M | Mar 10, 2017 |
| FY2016 | Sep 30, 2015 | $144.16M | Mar 10, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $675.46M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $534.79M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $639.81M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $654.23M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $543.49M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $465.77M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $492.41M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $548.18M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $491.61M | Mar 8, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $264.42M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $202.36M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $215.85M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $183.45M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $134.38M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $119.73M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $109.97M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $139.26M | Mar 25, 2020 |
| FY2017 | Dec 31, 2017 | $22.08M | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | $27.62M | Mar 9, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.54M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $40.96M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $73.83M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $52.69M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $24.82M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $12.80M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($8.74M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $20.71M | Mar 25, 2020 |
| FY2017 | Dec 31, 2017 | ($20.79M) | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | $5.02M | Mar 9, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $64.30M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $87.98M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $65.15M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $31.26M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $18.67M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($1.60M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $26.95M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $17.39M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($76.51M) | Mar 9, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.87M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $23.59M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $22.49M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $20.24M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $21.89M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $23.61M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $26.93M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $29.49M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $28.80M | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $26.70M | Mar 8, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.83M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $110.62M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $99.09M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $92.34M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $86.61M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $78.70M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $77.42M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $82.60M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $84.66M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $71.01M | Mar 9, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.61M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $74.06M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $108.35M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $40.26M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $4.63M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $46.11M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $24.45M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $10.10M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $24.12M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $38.60M | Mar 9, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $14.11M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $12.13M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $8.83M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $9.40M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $5.48M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $9.89M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $11.59M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $6.43M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $8.22M | Mar 9, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $935.20M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $949.79M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $571.63M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $560.47M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $511.85M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $453.87M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $468.92M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $443.52M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $431.27M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $426.74M | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $416.53M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $508.63M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $231.07M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $298.12M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $303.10M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $268.07M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $300.87M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $267.05M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $273.31M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $268.31M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $425.51M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $360.58M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $340.56M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $262.35M | Mar 11, 2024 |
| FY2023 | Dec 31, 2021 | $208.74M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $185.80M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $168.05M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $176.47M | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $157.96M | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $158.43M | Mar 8, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $214.82M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $208.04M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $26.64M | Feb 24, 2026 |
| FY2023 | Jan 1, 2023 | $25.10M | Mar 11, 2024 |
| FY2024 | Dec 31, 2022 | $25.10M | Feb 28, 2025 |
| FY2022 | Jan 1, 2022 | $26.65M | Mar 10, 2023 |
| FY2022 | Dec 31, 2021 | $26.65M | Mar 10, 2023 |
| FY2021 | Jan 1, 2021 | $23.97M | Mar 14, 2022 |
| FY2021 | Dec 31, 2020 | $23.97M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $21.99M | Mar 12, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $403.10M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $345.03M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $307.51M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $237.19M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $187.94M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $166.49M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $157.06M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $168.70M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $147.81M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $161.29M | Mar 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.80M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $68.25M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $89.37M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $70.27M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $61.76M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $84.94M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $72.29M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $53.91M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $69.35M | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $73.41M | Mar 8, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.50M | Feb 24, 2026 |
| FY2024 | Dec 31, 2024 | $287.50M | Feb 28, 2025 |
| FY2023 | Dec 31, 2023 | $60.00M | Mar 11, 2024 |
| FY2022 | Dec 31, 2022 | $95.00M | Mar 10, 2023 |
| FY2021 | Dec 31, 2021 | $112.50M | Mar 14, 2022 |
| FY2020 | Dec 31, 2020 | $116.84M | Mar 12, 2021 |
| FY2019 | Dec 31, 2019 | $145.01M | Mar 25, 2020 |
| FY2018 | Dec 31, 2018 | $114.20M | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | $122.70M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $141.20M | Mar 9, 2018 |